<p>2025 年 10 月 8 日- 下午 04:57</p>
<p><em>Navidea Biopharmaceuticals, Inc.申請破產</em></p>
<p>俄亥俄州哥倫布市 --（商業新聞）--Navidea Biopharmaceuticals, Inc.（“Navidea” 或 “公司”）是一家專注於精準免疫診斷劑和免疫治療藥物開發的生物製藥公司，今天宣佈於 2025 年 10 月 1 日在特拉華州美國破產法院（“法院”）根據美國破產法第 11 章第 V 小節提交了自願破產申請。</p>
<p>該申請旨在使公司能夠在繼續有限運營以保護債權人和利益相關者的價值的同時，有序重組其財務義務。公司打算利用第 11 章程序評估戰略選擇，保護其資產，並確保對債權人的公平對待。</p>
<p><strong>獲取案件信息</strong></p>
<p>Epiq Corporate Restructuring, LLC（“Epiq”）擔任公司第 11 章案件的索賠和通知代理。債權人、股東和其他相關方可以通過訪問 Epiq 網站獲取有關案件的更多信息，包括法院文件、索賠表格和關鍵日期，網址為：https://dm.epiq11.com/Navidea。此外，債權人、股東和其他相關方可以在案件網站上註冊，以免費接收所有已登記法院訴狀的電子副本。</p>
<p><strong>關於 Navidea</strong></p>
<p>Navidea Biopharmaceuticals, Inc.是一家專注於精準免疫診斷劑和免疫治療藥物開發的生物製藥公司。Navidea 正在基於其 Manocept 平台開發多種精準靶向產品，以通過識別疾病的部位和途徑來增強患者護理，並提高診斷準確性、臨牀決策和靶向治療。Navidea 的 Manocept 平台基於能夠特異性靶向在活化巨噬細胞上表達的 CD206 甘露糖受體的能力。Manocept 平台作為 Tc99m tilmanocept 的分子基礎，這是 Navidea 基於該平台開發和商業化的第一個產品。Navidea 的戰略是通過其多樣化的美國和外國專利及專利申請組合，市場化新產品並推進公司的產品管道，通過全球合作和商業化努力。有關更多信息，請訪問 www.navidea.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDg4NDM4MzlyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDg4NDM4MzlyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251008843839/en/</p>
<p>首席財務官 Craig A. Dais</p>
<p>cdais@navidea.com</p>
<p>(614)-822-2322</p>
<p>來源：Navidea Biopharmaceuticals, Inc.</p>

NAVBQ

<p>Navidea Biopharmaceuticals, Inc. 於 2025 年 10 月 1 日在特拉華州美國破產法院申請了第 11 章破產。該公司旨在重組其財務義務，同時繼續有限的運營，以為債權人和利益相關者保留價值。Navidea 專注於開發精準免疫診斷劑和免疫治療藥物，利用其 Manocept 平台提高診斷準確性和治療效果。Epiq Corporate Restructuring, LLC 正在管理該破產案件，為債權人和相關方提供信息</p>

<p>10/08/2025 - 04:57 PM</p>
<div class="lb-trans"><p>2025 年 10 月 8 日- 下午 04:57</p>
</div><p><em>Navidea Biopharmaceucitals, Inc. files for Bankruptcy</em></p>
<div class="lb-trans"><p><em>Navidea Biopharmaceuticals, Inc.申請破產</em></p>
</div><p>COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”), a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) on October 1, 2025.</p>
<div class="lb-trans"><p>俄亥俄州哥倫布市 --（商業新聞）--Navidea Biopharmaceuticals, Inc.（“Navidea” 或 “公司”）是一家專注於精準免疫診斷劑和免疫治療藥物開發的生物製藥公司，今天宣佈於 2025 年 10 月 1 日在特拉華州美國破產法院（“法院”）根據美國破產法第 11 章第 V 小節提交了自願破產申請。</p>
</div><p>The filing is intended to enable the Company to pursue an orderly restructuring of its financial obligations while continuing limited operations to preserve value for creditors and stakeholders. The Company intends to use the Chapter 11 process to evaluate strategic alternatives, protect its assets, and ensure fair treatment of creditors.</p>
<div class="lb-trans"><p>該申請旨在使公司能夠在繼續有限運營以保護債權人和利益相關者的價值的同時，有序重組其財務義務。公司打算利用第 11 章程序評估戰略選擇，保護其資產，並確保對債權人的公平對待。</p>
</div><p><strong>Access to Case Information</strong></p>
<div class="lb-trans"><p><strong>獲取案件信息</strong></p>
</div><p>Epiq Corporate Restructuring, LLC (“Epiq”) is serving as the claims and noticing agent for the Company’s Chapter 11 case. Creditors, shareholders, and other interested parties can obtain additional information about the case, including court filings, claim forms, and key dates, by visiting the Epiq website at: https://dm.epiq11.com/Navidea. Additionally, creditors, shareholders, and other interested parties can register on the case website to receive electronic copies of to all docketed Court pleadings, free of charge.</p>
<div class="lb-trans"><p>Epiq Corporate Restructuring, LLC（“Epiq”）擔任公司第 11 章案件的索賠和通知代理。債權人、股東和其他相關方可以通過訪問 Epiq 網站獲取有關案件的更多信息，包括法院文件、索賠表格和關鍵日期，網址為：https://dm.epiq11.com/Navidea。此外，債權人、股東和其他相關方可以在案件網站上註冊，以免費接收所有已登記法院訴狀的電子副本。</p>
</div><p><strong>About Navidea</strong></p>
<div class="lb-trans"><p><strong>關於 Navidea</strong></p>
</div><p>Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea’s strategy is to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts through its diverse portfolio of issued US and foreign patents and patent applications. For more information, visit www.navidea.com.</p>
<div class="lb-trans"><p>Navidea Biopharmaceuticals, Inc.是一家專注於精準免疫診斷劑和免疫治療藥物開發的生物製藥公司。Navidea 正在基於其 Manocept 平台開發多種精準靶向產品，以通過識別疾病的部位和途徑來增強患者護理，並提高診斷準確性、臨牀決策和靶向治療。Navidea 的 Manocept 平台基於能夠特異性靶向在活化巨噬細胞上表達的 CD206 甘露糖受體的能力。Manocept 平台作為 Tc99m tilmanocept 的分子基礎，這是 Navidea 基於該平台開發和商業化的第一個產品。Navidea 的戰略是通過其多樣化的美國和外國專利及專利申請組合，市場化新產品並推進公司的產品管道，通過全球合作和商業化努力。有關更多信息，請訪問 www.navidea.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEwMDg4NDM4MzlyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251008843839r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251008843839/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251008843839/en/</p>
</div><p>Craig A. Dais, Chief Financial Officer</p>
<div class="lb-trans"><p>首席財務官 Craig A. Dais</p>
</div><p>cdais@navidea.com</p>
<div class="lb-trans"><p>cdais@navidea.com</p>
</div><p>(614)-822-2322</p>
<div class="lb-trans"><p>(614)-822-2322</p>
</div><p>Source: Navidea Biopharmaceuticals, Inc.</p>
<div class="lb-trans"><p>來源：Navidea Biopharmaceuticals, Inc.</p>
</div>

Navidea Biopharmaceuticals, Inc.申請破產保護 | NAVB 股票新聞